Synapse - Works

Results (5712)

Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Meeting Abstract

DiNardo, C. D.; Dohner, H.; Zeidan, A. M.; Schuh, A. C.; Vyas, P.; Stein, E. M.; Wei, A. H.; de Botton, S.; Chen, C.; Lord-Bessen, J.; more...
Blood (2021)

Fulltext@MSK | Save

Single-agent ibrutinib versus real-world (RW) treatments for patients with previously untreated chronic lymphocytic leukemia (CLL): Adjusted comparison of RESONATE-2™ with the CLLEAR and Lyon-Sud RW databases

Journal Article

Doubek, M.; Smolej, M. L.; Simkovic, M.; Panovska, A.; Urbanova, R.; Lysak, D.; Callet-Bauchu, E.; Bachy, E.; Baseggio, L.; Ferrant, E.; more...
Blood (2021)

Fulltext@MSK | Save

Single cell ATAC lineage deconvolution reveals overlapping subclones in epigenetically distinct AML samples

Meeting Abstract

Dilip, D.; Koche, R.; Menghrajani, K.; Melnick, A.; Elemento, O.; Levine, R. L.; Glass, J. L.
Blood (2021)

Fulltext@MSK | Save

Clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) data hub

Meeting Abstract

Desai, P.; Goldberg, A. D.; Anderson, K. C.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Redd, R. A.; Roboz, G. J.; Sehn, L. H.; Sekeres, M. A.; more...
Blood (2021)

Fulltext@MSK | Save

Molecular and genetic characterization of tumor samples from patients with relapsed or refractory follicular lymphoma identifies factors influencing response to tazemetostat

Meeting Abstract

Dave, S. S.; Happ, L.; Yasso, C.; Salles, G.; Batlevi, C. L.; Phillips, T.; Yang, J.; Adib, D.; Michaud, N. R.; Morschhauser, F.
Blood (2021)

Fulltext@MSK | Save

MAJIC: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

Meeting Abstract

Davids, M. S.; Mato, A. R.; Hum, J.; Wargo, S.; Emeribe, U.; Shahkarami, M.; Sokolowski, K.; Biondo, J. M. L.; Abhyankar, S.; Hermann, R.; more...
Blood (2021)

Fulltext@MSK | Save

Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the OPTIC trial

Meeting Abstract

Deininger, M. W.; Apperley, J. F.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; De Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
Blood (2021)

Fulltext@MSK | Save

Nutrition as a predictor of microbiome injury in allo-HCT

Meeting Abstract

Dai, A.; Adintori, P. A.; Docampo, M. D.; Brambilla, C. Z.; Buchan, M. L.; Gomes, A. L.; Burgos da Silva, M. D.; Markey, K. A.; Devlin, S. M.; Clurman, A.; more...
Blood (2021)

Fulltext@MSK | Save

Normalization of the immune microenvironment during lenalidomide maintenance is associated with sustained MRD negativity in patients with multiple myeloma

Meeting Abstract

Coffey, D. G.; Maura, F.; Gonzalez-Kozlova, E.; Diaz-Mejia, J.; Luo, P.; Zhang, Y.; Xu, Y.; Warren, E. H.; Smith, E. L.; Cho, H. J.; more...
Blood (2021)

Fulltext@MSK | Save

An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) failing prior TKI therapies

Meeting Abstract

Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Apperley, J. F.; Deininger, M. W.; de Lavallade, H.; more...
Blood (2021)

Fulltext@MSK | Save